Related references
Note: Only part of the references are listed.Skin advanced glycation end products as biomarkers of photosensitivity in schizophrenia
Eriko Tani et al.
INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH (2019)
The role of hormonal, metabolic and inflammatory biomarkers on sleep and appetite in drug free patients with major depression: A systematic review
Mariarita Caroleo et al.
JOURNAL OF AFFECTIVE DISORDERS (2019)
Prognosis and improved outcomes in major depression: a review
Christoph Kraus et al.
TRANSLATIONAL PSYCHIATRY (2019)
Non-invasive skin autofluorescence, blood and urine assays of the advanced glycation end product (AGE) pentosidine as an indirect indicator of AGE content in human bone
Yoshikuni Kida et al.
BMC MUSCULOSKELETAL DISORDERS (2019)
Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies
Kurt A. Jellinger
JOURNAL OF NEURAL TRANSMISSION (2018)
Biomarkers for Alzheimer Disease: Classical and Novel Candidates' Review
Nadia El Kadmiri et al.
NEUROSCIENCE (2018)
Carbonyl Stress and Microinflammation-Related Molecules as Potential Biomarkers in Schizophrenia
Tohru Ohnuma et al.
FRONTIERS IN PSYCHIATRY (2018)
SPECT and PET imaging in Alzheimer's disease
Varvara Valotassiou et al.
ANNALS OF NUCLEAR MEDICINE (2018)
Advanced Glycation End Product (AGE) Accumulation in the Skin is Associated with Depression: The Maastricht Study
Fleur E. P. van Dooren et al.
DEPRESSION AND ANXIETY (2017)
Skin Autofluorescence Examination as a Diagnostic Tool for Mild Cognitive Impairment in Healthy People
Michiya Igase et al.
JOURNAL OF ALZHEIMERS DISEASE (2017)
Advanced Glycation End Products in Recent-Onset Psychosis Indicate Early Onset of Cardiovascular Risk
Julia M. Hagen et al.
JOURNAL OF CLINICAL PSYCHIATRY (2017)
Why do so many clinical trials of therapies for Alzheimer's disease fail?
Roy M. Anderson et al.
LANCET (2017)
Diagnosis and management of dementia with Lewy bodies Fourth consensus report of the DLB Consortium
Ian G. McKeith et al.
NEUROLOGY (2017)
High doses of antipsychotic polypharmacy are related to an increase in serum levels of pentosidine in patients with schizophrenia
Takahiro Sannohe et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2017)
High serum soluble tumor necrosis factor receptor 1 predicts poor treatment response in acute-stage schizophrenia
Shohei Nishimon et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2017)
Common neurodegenerative pathways in obesity, diabetes, and Alzheimer's disease
Subbiah Pugazhenthi et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2017)
Alpha-Synuclein as a Biomarker for Parkinson's Disease
Anzari Atik et al.
BRAIN PATHOLOGY (2016)
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Bob Olsson et al.
LANCET NEUROLOGY (2016)
PET and SPECT Radiotracers for Alzheimer's Disease
Killian Oukoloff et al.
CURRENT MEDICINAL CHEMISTRY (2015)
Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease
Sho-ichi Yamagishi et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2015)
Altered serum glyceraldehyde-derived advanced glycation end product (AGE) and soluble AGE receptor levels indicate carbonyl stress in patients with schizophrenia
Mayu Takeda et al.
NEUROSCIENCE LETTERS (2015)
Significance of Measurements of Peripheral Carbonyl Stress Markers in a Cross-sectional and Longitudinal Study in Patients With Acute-stage Schizophrenia
Narimasa Katsuta et al.
SCHIZOPHRENIA BULLETIN (2014)
Biomarkers in biological fluids for dementia with Lewy bodies
Sebastian Schade et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
Increased advanced glycation end-products (AGEs) assessed by skin autofluorescence in schizophrenia
Youssef Kouidrat et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2013)
Metabolism of Amyloid-β Protein May Be Affected in Depression
Hajime Baba et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
Correlations between brain-derived neurotrophic factor and clinical symptoms in medicated patients with major depression
Emi Satomura et al.
JOURNAL OF AFFECTIVE DISORDERS (2011)
Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia
Tohru Ohnuma et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2011)
Enhanced Carbonyl Stress in a Subpopulation of Schizophrenia
Makoto Arai et al.
ARCHIVES OF GENERAL PSYCHIATRY (2010)
A New Pathophysiological Aspect of S100B in Schizophrenia: Potential Regulation of S100B by Its Scavenger Soluble RAGE
Johann Steiner et al.
BIOLOGICAL PSYCHIATRY (2009)
Involvement of Toxic AGEs (TAGE) in the Pathogenesis of Diabetic Vascular Complications and Alzheimer's Disease
Masayoshi Takeuchi et al.
JOURNAL OF ALZHEIMERS DISEASE (2009)
Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: Results from the Juntendo University Schizophrenia Projects (JUSP)
Tohru Ohnuma et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2008)
Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: An overview of current clinical studies, evidence, and limitations
Douwe J. Mulder et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2006)
Diagnosis and management of dementia with Lewy bodies - Third report of the DLB consortium
IG McKeith et al.
NEUROLOGY (2005)
Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease
S Yamagishi et al.
MEDICAL HYPOTHESES (2005)
Simple non-invasive assessment of advanced glycation endproduct accumulation
R Meerwaldt et al.
DIABETOLOGIA (2004)
Crosslinking of α-synuclein by advanced glycation endproducts -: an early pathophysiological step in Lewy body formation?
G Münch et al.
JOURNAL OF CHEMICAL NEUROANATOMY (2000)
Share Paper
